Leveraging our more than 20 years of gene therapy leadership.
uniQure is delivering on the promise of gene therapy — single treatments with potentially curative results.
We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington’s disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS.
Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.
The finalists for the Amsterdam Science & Innovation Award 2021 are presented. The jury, led by Gigi Wang, and the public have selected nine finalists for the Innovation Award from all submissions from the Amsterdam knowledge and research institutes. The innovations and new technologies offer innovative solutions for a wide range of social issues. The finalists […]News
Thanks for all the votes! Per category, the participant with the most votes will go to the final. The ballot boxes are open! Vote for your favorite innovative idea that contributes to a better world. We have selected the pre-finalists of the Amsterdam Science & Innovation Award. You can now vote which ideas should be […]News
Halleh Ghorashi, Jeroen Kluck en Hergen Spits winnaars Impact Award 2021!News